Clinical Trials Logo

Filter by:
NCT ID: NCT05616052 Not yet recruiting - Weight Change, Body Clinical Trials

Comparison of Body Weight Change Through Different Smeglutide Administration Methods

Start date: December 1, 2022
Phase: Phase 4
Study type: Interventional

Investigators determined to detect the effect of smeglutide on body weight and metabolic indexes among overweight and obese participants through two different dosing programs.

NCT ID: NCT05615974 Suspended - Malignant Tumors Clinical Trials

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Start date: January 11, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors

NCT ID: NCT05615792 Completed - Clinical trials for 2019 Novel Coronavirus Disease

Observational Cohort of COVID-19 Patients in Hubei Province

OCCP-HP
Start date: February 1, 2020
Phase:
Study type: Observational

This study intends to use the relevant case data of COVID-19 in Hubei Province, using big data processing and mining methods to evaluate the effects of clinical indicators, drug use and genes on the clinical prognosis of COVID-19 patients, so as to provide a theoretical basis for the treatment of these diseases and reduce the mortality.

NCT ID: NCT05615727 Recruiting - Insomnia Clinical Trials

Intranasal Dexmedetomidine and Zolpidem for Treatment of Primary Insomnia

Start date: September 1, 2022
Phase: Phase 3
Study type: Interventional

Insomnia is a significant public health burden, increasing work absenteeism and health care costs in a large proportion of the population. It causes altered cognition, emotional disturbances, and reduced quality of life. The purpose of this study is to determine whether the sleep promoting effect of dexmedetomidine is superior to the conventional sleep promoting drug, zolpidem. The main outcome of this study is to measure the time taken to fall asleep. Investigators will also look at incidences of wakening after sleep onset, sleep quality and wake time during sleep.

NCT ID: NCT05615545 Recruiting - Sarcoma Clinical Trials

Cryoablation for Advanced Bone and Soft Tissue Tumors

Start date: March 10, 2022
Phase:
Study type: Observational

This is a single-center, open, retrospective clinical study of patients with metastatic/surgically unresectable bone and soft tissue sarcoma undergoing cryoablation of selected tumor lesions. All eligible patients were enrolled. Basic data and treatment methods of these patients were collected, and efficacy and safety were evaluated.

NCT ID: NCT05615519 Recruiting - Strabismus Clinical Trials

Validation of a Smartphone-based Intelligent Diagnosis and Measurement for Strabismus

Start date: December 2, 2022
Phase:
Study type: Observational

The current measurement methods of strabismus include the corneal light reflection method, prism alternate covering, etc., which especially rely on the subjective experience of doctors, and there is a large error between different measurers, leading to serious underestimation of strabismus prevalence and insufficient care for strabismus patients. Here, the investigators established and validated an artificial intelligence system to achieve an automatic diagnosis of strabismus based on patient-sourced videos of programmatic cover tests. Three-dimensional reconstruction methods are used to digitize the parameters of head and eye positions. This system has been integrated into a smartphone platform to be further validated through hospital-based and population-based clinical trials.

NCT ID: NCT05615142 Recruiting - NSCLC Clinical Trials

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Start date: December 15, 2021
Phase: Phase 1
Study type: Interventional

This pilot phase I trial aims to investigate the safety and tolerability of low dose radiotherapy (LDRT) and concurrent partial stereotactic body radiation therapy (SBRT) in combination with programmed cell death-1 (PD-1) inhibitors in Stage IV non-small cell lung cancer (NSCLC) patients who have failed standard therapy. At least 9 participants will be enrolled in this study. All will take part at West China Hospital, Sichuan University.

NCT ID: NCT05615129 Completed - Esophagus Cancer Clinical Trials

Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting

RICE-Chronos
Start date: October 1, 2021
Phase:
Study type: Observational

It is reported that compared to chemotherapy alone, immunochemotherapy has significantly improved the overall survival of patients with advanced metastatic ESCC. However, there are still more than 30% of patients who cannot benefit from this treatment modality. In addition to these factors, the time-of-day infusion and administration sequence of immunochemotherapy have been reported to be associated with tumor responses and overall survival. In this study, The investigators aimed to explore the roles of infusion time and administration sequence of immunochemotherapy in predicting tumor responses and overall survival in patients with advanced ESCC.

NCT ID: NCT05615116 Not yet recruiting - Crohn Disease Clinical Trials

Clinical Study on the Distribution of Digestive Tract Microbiota Before and After Ileocecal Resection in Crohn's Disease

Start date: November 15, 2022
Phase:
Study type: Observational

In this study, the microbiota sequencing was used to investigate the changes of microbiota in the terminal ileum and the middle part of ascending colon, the mesenteric adipose tissue of ileum and ascending mesocolon, and oral cavity of patients with Crohn's disease before and after ileocecal resection, so as to further explore the role of ileocecal region in inducing remission of disease.

NCT ID: NCT05615103 Recruiting - Esophageal Cancer Clinical Trials

The PET-CT Predicting Response to Immunochemotherapy in Esophageal Cancer

POSITRON
Start date: November 8, 2022
Phase:
Study type: Observational

Treatment with immune checkpoint inhibitors such as programmed death receptor 1 (PD-1 inhibitors) for advanced and metastatic esophageal squamous cell carcinoma (ESCC) significantly improves patients' overall survival compared to chemotherapy alone. Despite this milestone breakthrough, immunochemotherapy also has known limitations. Indeed, only 45-72% of patients achieved objective responses. It is urgent to find out easily-determined and convenient biomarkers to identify patients who will benefit from such treatment modality. Due to the luminal structure of the esophagus, the exact diameter of esophageal tumor cannot be precisely measured per RECIST 1.1. Moreover, the definition of the metastatic lymph node in which the short-axis lengths should be longer than 1.5 cm hinders the risk of missing the smaller metastatic lymph node foci. Thus, it is difficult to implement morphology-based criteria for evaluating the neoadjuvant immunochemotherapy response. The current study aimed to investigate the role of iPERCIST in predicting tumor response and the short-term overall survival of patients with locally advanced ESCC after neoadjuvant immunochemotherapy.